Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences

被引:32
作者
Saxena, A
Shriml, LM
Dean, M
Ali, IU [1 ]
机构
[1] NCI, Chemoprevent Branch, NIH, Bethesda, MD 20892 USA
[2] NINCDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Lab Genom Divers, NIH, Frederick, MD 21702 USA
基金
美国国家卫生研究院;
关键词
malignant gliomas; recurrence; genetic profiles;
D O I
10.1038/sj.onc.1202440
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant glial tumors (anaplastic astrocytomas and glioblastomas multiforme) arise mostly either from the progression of low grade precursor lesions or rapidly in a de novo fashion and contain distinct genetic alterations. There is, however, a third subset of malignant gliomas in which genetic lesions remain to be identified, Following surgical resection, all gliomas appear to have an inherent tendency to recur, Comparative molecular analysis of ten primary malignant gliomas (three anaplastic astrocytomas and seven glioblastomas multiforme) with their recurrences identified two distinct subgroups of recurrent tumors. In one group, primary tumors harbored genetic aberrations frequently associated with linear progression or ne novo formation pathways of glial tumorigenesis and maintained their genetic profiles upon recurrence. In the other subset with no detectable known genetic mutations at first presentation, the recurrent tumors sustained specific abnormalities associated with pathways of linear progression or ne novo formation. These included loss of genes on chromosomes 17 and 10, mutations in the p53 gene, homozygous deletion of the DMBTA1 and p16 and/or p15 genes and amplification and/or overexpression of CDK4 and alpha form of the PDGF receptor. Recurrent tumors from both groups also displayed an abnormal expression profile of the metalloproteinase, gel A, and its inhibitor, TIMP-2, consistent with their highly invasive behavior, Delineation of the molecular differences between malignant glioblastomas and their subsequent recurrences may have important implications for the development of rational clinical approaches for this neoplasm that remains refractory to existing therapeutic modalities.
引用
收藏
页码:1385 / 1390
页数:6
相关论文
共 35 条
[1]   CLONAL COMPOSITION OF GLIOBLASTOMA-MULTIFORME [J].
BERKMAN, RA ;
CLARK, WC ;
SAXENA, A ;
ROBERTSON, JT ;
OLDFIELD, EH ;
ALI, IU .
JOURNAL OF NEUROSURGERY, 1992, 77 (03) :432-437
[2]   Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer [J].
Berns, EMJJ ;
van Staveren, IL ;
Look, MP ;
Smid, M ;
Klijn, JGM ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1130-1136
[3]   Dominant-negative p53 mutations selected in yeast hit cancer hot spots [J].
Brachmann, RK ;
Vidal, M ;
Boeke, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4091-4095
[4]  
CHO Y, 1994, SCIENCE, V265, P1994
[5]   TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer [J].
Erber, R ;
Conradt, C ;
Homann, N ;
Enders, C ;
Finckh, M ;
Dietz, A ;
Weidauer, H ;
Bosch, FX .
ONCOGENE, 1998, 16 (13) :1671-1679
[6]  
FLEMING TP, 1992, CANCER RES, V52, P4550
[7]   A DE-NOVO P53 GERMLINE MUTATION AFFECTING CODON-151 IN A 6-YEAR-OLD CHILD WITH MULTIPLE TUMORS [J].
GUTIERREZ, MI ;
BHATIA, KG ;
BARREIRO, C ;
SPANGLER, G ;
SCHVARTZMANN, E ;
MURIEL, FS ;
MAGRATH, IT .
HUMAN MOLECULAR GENETICS, 1994, 3 (12) :2247-2248
[8]   TIMING AND ROLE OF P53 GENE MUTATION IN THE RECURRENCE OF GLIOMA [J].
HAYASHI, Y ;
YAMASHITA, J ;
YAMAGUCHI, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (02) :1145-1150
[9]  
Hermanson M, 1996, CANCER RES, V56, P164
[10]  
KERN SE, 1991, ONCOGENE, V6, P131